Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 30;45(5):131.
doi: 10.1007/s00296-025-05886-4.

Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review

Jean-Baptiste Vulsteke  1   2   3 , Petra De Haes  4   5   6 , Minoru Satoh  7   8 , Ben Van Cleynenbreugel  9   10 , Benoit Beuselinck  11   12 , Xavier Bossuyt  13   14 , Ellen De Langhe  15   6   16
Affiliations
Review

Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review

Jean-Baptiste Vulsteke et al. Rheumatol Int. .

Abstract

To describe the clinical features and cancer risk in patients with dermatomyositis (DM) and anti-TIF1β autoantibodies without other DM-specific autoantibodies (anti-TIF1β-monospecific DM) through a case-based review. Case report of anti-TIF1β-monospecific cancer-associated DM and literature review of cases of anti-TIF1β-monospecific DM. We describe a case of a person with cancer-associated DM in whom we identified anti-TIF1β autoantibodies through immunoprecipitation-mass spectrometry. He had typical cutaneous involvement, mild myositis and a good response to medical therapy after curative treatment of an underlying renal cell cancer. A literature search of Pubmed and Scopus identified 9 more persons with anti-TIF1β-monospecific DM revealing a homogeneous phenotype with typical cutaneous involvement, mild to absent muscular involvement and absence of interstitial lung disease. Two out of ten (20%) had cancer-associated DM. Anti-TIF1β-monospecific DM represents a homogeneous subset of DM characterized by typical cutaneous involvement, mild to absent myositis and potentially an elevated cancer risk (20%). More cohort studies with adequate detection methods are needed to formally assess the cancer risk as compared to anti-TIF1γ and other DM-specific autoantibodies.

Keywords: Autoantibodies; Dermatomyositis; Idiopathic inflammatory myopathy; Myositis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The patient provided written informed consent. Competing interests: The authors declare no competing interests related to the work.

References

    1. Oldroyd A, Sergeant JC, New P et al (2019) The Temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58:650–655. https://doi.org/10.1093/rheumatology/key357 - DOI - PubMed
    1. Lundberg IE, Fujimoto M, Vencovsky J et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7:86. https://doi.org/10.1038/s41572-021-00321-x - DOI - PubMed
    1. Espinosa-Ortega F, Lodin K, Dastmalchi M et al (2024) Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network. Semin Arthritis Rheum 68:152529. https://doi.org/10.1016/j.semarthrit.2024.152529 - DOI - PubMed
    1. Fujimoto M, Hamaguchi Y, Kaji K et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522. https://doi.org/10.1002/art.33403 - DOI - PubMed
    1. Satoh M, Chan JYF, Ross SJ et al (2012) Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis. Arthritis Res Ther 14:R79. https://doi.org/10.1186/ar3802 - DOI - PubMed - PMC

LinkOut - more resources